Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors

Irina V. Balyasnikova*, Melanie S. Prasol, Sherise D. Ferguson, Yu Han, Atique U. Ahmed, Margarita Gutova, Alex L. Tobias, Devkumar Mustafi, Esther Rincón, Lingjiao Zhang, Karen S. Aboody, Maciej S. Lesniak

*Corresponding author for this work

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Treatment options of glioblastoma multiforme are limited due to the blood-brain barrier (BBB). In this study, we investigated the utility of intranasal (IN) delivery as a means of transporting stem cell-based antiglioma therapeutics. We hypothesized that mesenchymal stem cells (MSCs) delivered via nasal application could impart therapeutic efficacy when expressing TNF-related apoptosis-inducing ligand (TRAIL) in a model of human glioma. 111 In-oxine, histology and magnetic resonance imaging (MRI) were utilized to track MSCs within the brain and associated tumor. We demonstrate that MSCs can penetrate the brain from nasal cavity and infiltrate intracranial glioma xenografts in a mouse model. Furthermore, irradiation of tumor-bearing mice tripled the penetration of 111In -oxine-labeled MSCs in the brain with a fivefold increase in cerebellum. Significant increase in CXCL12 expression was observed in irradiated xenograft tissue, implicating a CXCL12-dependent mechanism of MSCs migration towards irradiated glioma xenografts. Finally, MSCs expressing TRAIL improved the median survival of irradiated mice bearing intracranial U87 glioma xenografts in comparison with nonirradiated and irradiated control mice. Cumulatively, our data suggest that IN delivery of stem cell-based therapeutics is a feasible and highly efficacious treatment modality, allowing for repeated application of modified stem cells to target malignant glioma.

Original languageEnglish (US)
Pages (from-to)140-148
Number of pages9
JournalMolecular Therapy
Volume22
Issue number1
DOIs
StatePublished - Jan 1 2014

Fingerprint

Mesenchymal Stromal Cells
Brain Neoplasms
Glioma
Heterografts
Survival
TNF-Related Apoptosis-Inducing Ligand
Stem Cells
Oxyquinoline
Therapeutics
Nasal Cavity
Brain
Glioblastoma
Blood-Brain Barrier
Nose
Cerebellum
Cell Movement
Histology
Magnetic Resonance Imaging
Neoplasms

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Balyasnikova, Irina V. ; Prasol, Melanie S. ; Ferguson, Sherise D. ; Han, Yu ; Ahmed, Atique U. ; Gutova, Margarita ; Tobias, Alex L. ; Mustafi, Devkumar ; Rincón, Esther ; Zhang, Lingjiao ; Aboody, Karen S. ; Lesniak, Maciej S. / Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors. In: Molecular Therapy. 2014 ; Vol. 22, No. 1. pp. 140-148.
@article{a7dd8e5876744470a45c618ed3866099,
title = "Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors",
abstract = "Treatment options of glioblastoma multiforme are limited due to the blood-brain barrier (BBB). In this study, we investigated the utility of intranasal (IN) delivery as a means of transporting stem cell-based antiglioma therapeutics. We hypothesized that mesenchymal stem cells (MSCs) delivered via nasal application could impart therapeutic efficacy when expressing TNF-related apoptosis-inducing ligand (TRAIL) in a model of human glioma. 111 In-oxine, histology and magnetic resonance imaging (MRI) were utilized to track MSCs within the brain and associated tumor. We demonstrate that MSCs can penetrate the brain from nasal cavity and infiltrate intracranial glioma xenografts in a mouse model. Furthermore, irradiation of tumor-bearing mice tripled the penetration of 111In -oxine-labeled MSCs in the brain with a fivefold increase in cerebellum. Significant increase in CXCL12 expression was observed in irradiated xenograft tissue, implicating a CXCL12-dependent mechanism of MSCs migration towards irradiated glioma xenografts. Finally, MSCs expressing TRAIL improved the median survival of irradiated mice bearing intracranial U87 glioma xenografts in comparison with nonirradiated and irradiated control mice. Cumulatively, our data suggest that IN delivery of stem cell-based therapeutics is a feasible and highly efficacious treatment modality, allowing for repeated application of modified stem cells to target malignant glioma.",
author = "Balyasnikova, {Irina V.} and Prasol, {Melanie S.} and Ferguson, {Sherise D.} and Yu Han and Ahmed, {Atique U.} and Margarita Gutova and Tobias, {Alex L.} and Devkumar Mustafi and Esther Rinc{\'o}n and Lingjiao Zhang and Aboody, {Karen S.} and Lesniak, {Maciej S.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1038/mt.2013.199",
language = "English (US)",
volume = "22",
pages = "140--148",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "1",

}

Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors. / Balyasnikova, Irina V.; Prasol, Melanie S.; Ferguson, Sherise D.; Han, Yu; Ahmed, Atique U.; Gutova, Margarita; Tobias, Alex L.; Mustafi, Devkumar; Rincón, Esther; Zhang, Lingjiao; Aboody, Karen S.; Lesniak, Maciej S.

In: Molecular Therapy, Vol. 22, No. 1, 01.01.2014, p. 140-148.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Intranasal delivery of mesenchymal stem cells significantly extends survival of irradiated mice with experimental brain tumors

AU - Balyasnikova, Irina V.

AU - Prasol, Melanie S.

AU - Ferguson, Sherise D.

AU - Han, Yu

AU - Ahmed, Atique U.

AU - Gutova, Margarita

AU - Tobias, Alex L.

AU - Mustafi, Devkumar

AU - Rincón, Esther

AU - Zhang, Lingjiao

AU - Aboody, Karen S.

AU - Lesniak, Maciej S.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Treatment options of glioblastoma multiforme are limited due to the blood-brain barrier (BBB). In this study, we investigated the utility of intranasal (IN) delivery as a means of transporting stem cell-based antiglioma therapeutics. We hypothesized that mesenchymal stem cells (MSCs) delivered via nasal application could impart therapeutic efficacy when expressing TNF-related apoptosis-inducing ligand (TRAIL) in a model of human glioma. 111 In-oxine, histology and magnetic resonance imaging (MRI) were utilized to track MSCs within the brain and associated tumor. We demonstrate that MSCs can penetrate the brain from nasal cavity and infiltrate intracranial glioma xenografts in a mouse model. Furthermore, irradiation of tumor-bearing mice tripled the penetration of 111In -oxine-labeled MSCs in the brain with a fivefold increase in cerebellum. Significant increase in CXCL12 expression was observed in irradiated xenograft tissue, implicating a CXCL12-dependent mechanism of MSCs migration towards irradiated glioma xenografts. Finally, MSCs expressing TRAIL improved the median survival of irradiated mice bearing intracranial U87 glioma xenografts in comparison with nonirradiated and irradiated control mice. Cumulatively, our data suggest that IN delivery of stem cell-based therapeutics is a feasible and highly efficacious treatment modality, allowing for repeated application of modified stem cells to target malignant glioma.

AB - Treatment options of glioblastoma multiforme are limited due to the blood-brain barrier (BBB). In this study, we investigated the utility of intranasal (IN) delivery as a means of transporting stem cell-based antiglioma therapeutics. We hypothesized that mesenchymal stem cells (MSCs) delivered via nasal application could impart therapeutic efficacy when expressing TNF-related apoptosis-inducing ligand (TRAIL) in a model of human glioma. 111 In-oxine, histology and magnetic resonance imaging (MRI) were utilized to track MSCs within the brain and associated tumor. We demonstrate that MSCs can penetrate the brain from nasal cavity and infiltrate intracranial glioma xenografts in a mouse model. Furthermore, irradiation of tumor-bearing mice tripled the penetration of 111In -oxine-labeled MSCs in the brain with a fivefold increase in cerebellum. Significant increase in CXCL12 expression was observed in irradiated xenograft tissue, implicating a CXCL12-dependent mechanism of MSCs migration towards irradiated glioma xenografts. Finally, MSCs expressing TRAIL improved the median survival of irradiated mice bearing intracranial U87 glioma xenografts in comparison with nonirradiated and irradiated control mice. Cumulatively, our data suggest that IN delivery of stem cell-based therapeutics is a feasible and highly efficacious treatment modality, allowing for repeated application of modified stem cells to target malignant glioma.

UR - http://www.scopus.com/inward/record.url?scp=84891807513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891807513&partnerID=8YFLogxK

U2 - 10.1038/mt.2013.199

DO - 10.1038/mt.2013.199

M3 - Article

C2 - 24002694

AN - SCOPUS:84891807513

VL - 22

SP - 140

EP - 148

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 1

ER -